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Background: Blood transfusions have the potential to improve graft survival, induce sensitization, and transmit
infections. Current clinical practice is to minimize transfusions in renal transplantation candidates, but it is unclear if
the evidence continues to support pre-transplant transfusion avoidance. Changes in the Medicare prospective
payment system may increase transfusion rates. Thus there is a need to re-evaluate the literature to improve the
management options for renal transplant candidates.
Methods: A review applying a systematic approach and conducted using MEDLINE®, Embase®, and the Cochrane
Library for English-language publications (timeframe: 01/1984–03/2011) captured 180 studies and data from
publically available registries and assessed the impact of transfusions on allosensitization and graft survival, and the
impact of allosensitization on graft survival and wait time.
Results: Blood transfusions continued to be a major cause of allosensitization, with allosensitization associated with
increased rejection and graft loss, and longer wait times to transplantation. Although older studies showed a
beneficial effect of transfusion on graft survival, this benefit has largely disappeared in the post-cyclosporine era
due to improved graft outcomes with current practice. Recent data suggested that it may be the donor-specific
antibody component of allosensitization that carried the risk to graft outcomes.
Conclusions: Results of this review indicated that avoiding transfusions whenever possible is a sound management
option that could prevent detrimental effects in patients awaiting kidney transplantation.
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During the early 1980s, many transplant professionals
administered transfusions prior to renal transplant to pa-
tients to improve renal graft survival [1]. A decade later
few continued to do so, as the risk of sensitization, pos-
sible transmission of infection, and improved transplan-
tation outcomes without pre-transplant transfusions did
not justify pre-transplant transfusions [2].
The need for red blood cell transfusions for patients with
anemia waiting for renal transplantation also decreased* Correspondence: scornik@pathology.ufl.edu
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reproduction in any medium, provided the orwith the introduction of erythropoiesis-stimulating agents
(ESAs), which are now routinely used in non-emergent
situations [3]. However, changes in the Medicare prospec-
tive payment system for end-stage renal disease introduced
in 2011 [4,5] may increase the use of transfusions. Recent
data from the United States Renal Data System (USRDS)
reported that the percentage of patients who received at
least 1 transfusion increased from 2.4% to 3.0%, a relative
increase in transfusion rates of 24% over a 1-year period to
September 2011 [6].
A recent Agency for Healthcare Research and Quality
(AHRQ) review [7,8] suggested that pre-transplant transfu-
sion resulted in a neutral to beneficial effect on graft rejec-
tion, graft survival, and patient survival compared with no
transfusion. However, these benefits were reported mostlyLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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drugs and solid phase technology to measure sensitization,
and the authors acknowledged that strength of the evi-
dence was low. Thus, the evidence for pre-transplant pa-
tient management needs re-evaluation to assist patient
management.
This study aimed to review the literature and publi-
cally available registry data to determine the relation-
ships among pre-transplant transfusion, allosensitization,
graft outcomes, and wait time, focusing on the data most
relevant to current practice.
Methods
A literature review using a systematic approach was
conducted with the HERON Systematic Review Data-
base, a bespoke structured query language-based inter-
net database. In addition, data were extracted from
publically available registry databases. The objectives
were to directly assess the impact of pre-transplant
transfusions on allosensitization (objective 1) and graft
outcomes (objective 2), and the impact of the resulting
allosensitization on graft outcomes (objective 3) and wait
time (objective 4).
Data sources
MEDLINE®, Embase®, and the Cochrane Library were
searched for English-language publications. For objec-
tives 1 and 2 (transfusion), a timeframe from January 1,
1984 to March 23, 2011 was used because of the consi-
derable change in pre-transplant transfusion policy after
the FDA approval of cyclosporine as an immunosup-
pressant in November 1983 [9]. For objectives 3 and 4
(allosensitization), a timeframe from January 1, 2001 to
March 23, 2011 was used because data collection was
limited to the most relevant and current studies, given that
the recent technological developments in allosensitization
measurement would have reduced the applicability of
older publications to current clinical practice.
Six transplantation registries were searched for patient-
level data: the Australia and New Zealand Dialysis and
Transplant Registry (ANZDATA; http://www.anzdata.org.
au/v1/index.html), Collaborative Transplant Study (CTS;
http://www.ctstransplant.org/public/publications.jsp), United
Network for Organ Sharing (UNOS; http://www.unos.org/),
USRDS (http://www.usrds.org/), American Society of Trans-
plantation (AST; http://www.a-s-t.org/), and American
Association of Blood Banks (AABB; http://www.aabb.
org/Pages/Homepage.aspx). The AST and AABB did
not yield any data for inclusion in this study.
Search strategy for literature review
The search strategy involved 5 primary facets (comprised of
medical subject headings [MeSH], keywords, and Emtree
terms [used to index the Embase database], as appropriate)that were combined to answer the different study objec-
tives; these facets focused on organ, antibody, transfusion,
transplantation, and outcome. The disease area of interest
was kidney transplantation. The use of an organ facet ra-
ther than a specific kidney facet ensured that studies
enrolling potential transplant patients who did not proceed
to transplant were captured. An outcome facet was re-
quired to identify studies where allosensitization was asso-
ciated with wait time and/or renal allograft survival.
A search sample is provided in Additional file 1.
Study eligibility, selection, and data extraction for
literature review
All study designs were included. Studies involving pre-
and post-renal transplant patients with chronic kidney
disease, end-stage renal disease, or dialysis, who had re-
ceived transfusions of leukoreduced or non-leukoreduced
red blood cell units, as well as whole blood, were included.
There were no restrictions on age, gender, country, or
race. Animal studies, laboratory and validation studies of
clinical assays, case studies, conference abstracts and pub-
lication, review and editorial articles, and non-English
publications were excluded.
Bibliographic details and abstracts of all citations iden-
tified by the literature search were downloaded into the
HERON Systematic Review Database. A team of re-
viewers independently determined the eligibility of each
publication by applying the eligibility criteria to each
citation. Citations and then full-text papers were screened
by 2 independent reviewers, and any discrepancies be-
tween reviewers were reconciled by a third independent
reviewer.
Eligible studies were extracted to pre-defined data ex-
traction grids. Where > 1 publication was identified that
described a single trial, data were compiled into a single
entry to avoid double-counting of patients. Data extracted
included study design, patient population characteristics,
degree of sensitization as measured by cytotoxicity (panel
reactive antibodies [PRA]; %) or solid phase techniques,
degree of allosensitization as measured by presence of
donor-specific antibodies (DSAs; %), rates of pre-transplant
mortality in allosensitized patients (%), median wait time
to transplant (days, months, years), patients awaiting trans-
plantation at specific time points (%), graft survival rate
(%; at 3, 6, 12, 24, 36, 60, 120, and 360 months), pa-
tient survival rate (%; at 3, 6, 12, 24, 36, 60, 120, and
360 months), and incidence of acute, chronic, and antibody-
mediated rejection (%).
Following data extraction, additional criteria were
applied to the included studies to identify the most ap-
propriate data for each objective. Non-peer-reviewed
publications were excluded, as they were assumed to
contain less reliable data than peer-reviewed publica-
tions. In addition, studies comparing different types of
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as these studies do not directly answer the review objec-
tives (comparing transfusion vs. no transfusion). Similarly,
studies presenting data in an unsuitable format (e.g. no
numerical data, data for one patient group only, or data
for time points different from those of interest in the re-
view) were excluded from the analysis as they could not
be shown in graphical format for comparison with other
studies.
Data analysis
The quality of the studies included in the literature re-
view was assessed using the Downs and Black checklist
[10]. P-values and statistics are unadjusted and reported
as stated in their original publications except where indi-
cated. Results are presented in percentages for specific
populations of patients (e.g. transfused and sensitized,
transfused and non-sensitized). When not reported,
these percentages were calculated from the study data.
In studies where patients could be grouped in 1 category
(e.g. sensitized, non-sensitized), patient numbers were
pooled to calculate percentages. Where appropriate, all
time points with data available were plotted; in some
cases, key time points only were plotted (e.g. 12 months)
due to a lack of data at other time points.
Qualitative analysis was conducted, including expert
review by specialists in renal transplantation. Quantita-
tive pooled analysis was not considered appropriate due
to the heterogeneity in the study designs and patient
populations.
Results
A total of 7494 citations were identified, of which 206 ci-
tations relating to 180 studies were relevant to the objec-
tives. Of these, 62 studies were summarized (Figure 1).
The Downs and Black [10] quality score for these studies
ranged from 13 to 22 out of a possible score of 26. Al-
though there is no definitive cut-off for an acceptable
score, a recent publication on evidence assessment
considered > 14 as acceptable [11]. Using this criteria,
majority of the studies were considered to be of acceptable
quality, and only 6 were considered to be of poor quality
[1,12-16].
The impact of pre-transplant transfusion on
allosensitization
All studies included in the analysis reported a detrimental
effect of pre-transplant transfusion on allosensitization
(Figure 2): a significant detrimental effect was reported in
6 studies [1,17-21] while a non-significant detrimental
effect was reported in the remaining 5 studies [22-26].
In general, the rate of allosensitization was higher in pa-
tients receiving transfusion compared with patients not
transfused (Figure 2A). Allosensitization was also influencedby the number of pre-transplant transfusions, with an in-
creased number of prior transfusions augmenting the
risk of allosensitization (Figure 2B) [19,21,22,26].
The USRDS 2010 annual report confirmed the sensi-
tizing effect of transfusions. Patients receiving transfu-
sions had a higher risk of sensitization compared with
those not receiving transfusions. Parous females receiv-
ing pre-transplant transfusions were at increased risk of
sensitization compared with non-parous females (odds
ratio [OR] for sensitization with transfusion compared
with no transfusion for parous females vs. non-parous
females [PRA level]: 1.43 vs. 1.03 [> 0%], 1.44 vs. 1.08
[≥ 10%], 1.51 vs. 1.10 [≥ 20%], 1.61 vs. 1.12 [≥ 50%],
and 1.76 vs. 1.26 [≥ 80%]) [27]. Males had a higher risk
of sensitization after pre-transplant transfusion com-
pared with non-parous females (OR for sensitization with
transfusion compared with no transfusion for males vs.
non-parous females [PRA level]: 1.17 vs. 1.03 [> 0%], 1.43
vs. 1.08 [≥ 10%], 1.59 vs. 1.10 [≥ 20%], 1.86 vs. 1.12 [≥ 50%],
and 2.38 vs. 1.26 [≥ 80%]) [27], although the influence of
previous transplants was not assessed.
The impact of pre-transplant transfusions on allograft
outcomes
Most studies reported a beneficial effect of pre-transplant
transfusion on graft survival at 12 months (Figure 3A):
5 studies reported a significant beneficial effect [25,28-31],
and 4 studies a non-significant beneficial effect [1,32-34].
In contrast, a non-significant detrimental effect of pre-
transplant transfusions on graft survival was reported
in 5 studies [2,35-38]. A possible reason for the con-
flict between studies is the higher 1-year graft survival
in patients without pre-transplant transfusion, typical of
current outcomes, compared with older reports. Figure 3B
indicates that the beneficial effect of pre-transplant trans-
fusions was observed when graft survival rates in patients
without pre-transplant transfusion were low, with the dif-
ference in graft survival in patients receiving or not recei-
ving pre-transplant transfusions becoming less apparent
as graft outcomes improved over time.
The impact of allosensitization on allograft outcomes
Most studies reported a detrimental effect of allosensitization
on graft rejection: 9 studies reported a significant detrimental
effect [13,14,39-45], and 7 studies reported a non-significant
detrimental effect [12,15,16,46-49] (Figure 4). In contrast, 6
studies reported a non-detrimental effect of allosensitization
on graft rejection [50-55]. Of these, 2 restricted the analysis
to B cell antibodies [51,54].
When considering graft survival, 6 studies reported a
significant detrimental effect of allosensitization on graft
survival [56-61] and 12 studies reported a non-significant
detrimental effect [13,16,47,48,50,51,54,57,62-65] (Figure 5).
In contrast, 2 studies reported a non-detrimental impact of
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Figure 1 PRISMA diagram depicting study flow through the review. *The number of studies does not sum to 180 across all objectives since
a study may answer more than one objective. †The number of studies for each figure does not sum to the number of studies summarized since
a study may be presented in different figures or multiple parts of a single figure. Not peer-reviewed: studies published in non-peer-reviewed
journals (specifically Clinical Transplants and Transplantation Proceedings). Comparison not of interest: includes comparing various types or volume
of transfusion (e.g. donor specific versus random); Outcome reporting: data for the outcome have not been reported in a format suitable for
graphical representation (e.g. outcomes reported for one patient group only, outcome was drawn from a general conclusion in the text, time
points were different from those selected for extraction [3, 6, 12, 24, 36, 60, 120, and 360 months], or outcomes were impacted by the different
antibody detection techniques used in the study).
Scornik et al. BMC Nephrology 2013, 14:217 Page 4 of 12
http://www.biomedcentral.com/1471-2369/14/217allosensitization on graft survival. Two additional stu-
dies found no effect of B-cell antibodies on graft sur-
vival [47,62].
Overall, allosensitization was linked with higher rates
of graft rejection and lower rates of graft survival com-
pared with non-sensitized patients. In a recently pub-
lished study, the incidence of rejection was significantly
higher in patients with sensitization (PRA ≥ 10%; 58.8%
patients with rejection vs. 23.3% patients without rejec-
tion) than in patients without sensitization (PRA < 10%;
35.3% patients with rejection vs. 76.8% patients without
rejection) [14]. Similarly, a recent study reported lower
graft survival in sensitized patients compared with non-sensitized patients (1 year: 85% vs. 95%; 3 years: 75% vs.
94%; 8 years: 60.6% vs. 83%; P < 0.001) [57]. One study
found no significant differences in either rejection or
graft survival in sensitized patients compared with non-
sensitized patients [54].
Considering the impact of DSAs, 8 of the 9 studies
reported that the presence of DSAs was associated with
more acute graft rejections [14,50,52,66-71], with 2 stu-
dies reporting significant differences between groups
[67,71] (Figure 6A). In addition, DSAs were associated
with lower graft survival in 5 out of 6 studies investiga-
ting this relationship [47,50,52,57,71], with 2 studies
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111 11% 31% CDC PRA > 20% NR
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Figure 2 Impact of pre-transplant transfusion on allosensitization. (A) Proportion of patients sensitized stratified by pre-transplant
transfusion status. (B) Risk of allosensitization by number of pre-transplant transfusions. *Significant difference as reported in the original
publication; †represents sensitization measurement not explicit, but identified according to the text; ‡data reported for 0–5 transfusion vs. > 5
transfusions; values have been rounded to the nearest integer. NOTE: Additional calculation has been performed to allow for comparison
between the populations of interest. Therefore, the numbers presented differ from those presented in the primary source publications with the
exception of Lim 1992, Direskeneli 1992, and Lietz 2003. CDC: complement-dependent cytotoxicity; ELISA: enzyme-linked immunosorbant assay;
FXCM: flow cytometry cross-match; HLA: human leukocyte antigen; Mixed: probable CDC + flow cytometry; MPC: mean peak channel; NR: not
reported; PRA: panel reactive antibodies; +ve: positive.
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in 3 studies, either with acute rejection [50] or graft
survival [41,66].
In the USRDS 2010 annual report, the risk of graft fail-
ure was higher in allosensitized versus non-allosensitized
patients (hazard ratio for PRA levels of 0%: 1.0; 1%–9%:
1.08; 10%–79%: 1.21; ≥ 80%: 1.41) [27], while the UNOS/
Scientific Registry of Transplant Recipients (UNOS/SRTR)
2010 annual report showed a decrease in long-term graft
survival (5 and 10 years) with increased PRA levels (i.e. in-
crease in allosensitization), irrespective of the donor type
(living or deceased) [73]. From the 2012 Organ Procure-
ment and Transplantation Network/Health Resources and
Services Administration (OPTN/HRSA) registry data,
Kaplan-Meier estimates of survival rates for kidney
transplants performed between 1997 and 2004 reported
that graft survival decreased with increased PRA levels
(patients with 0–9% PRA: survival rate of 91.8%, 82.5%,
and 72.2% for 1 year, 3 years, and 5 years, respectively; pa-
tients with 10%–79% PRA: survival rate of 89.6%, 77.4%,
and 65.7% for 1, 3, and 5 years, respectively; patientswith ≥ 80% PRA: survival rate of 88.4%, 74.6%, and 61.9%
for 1, 3, and 5 years, respectively) [74].
The impact of allosensitization on wait time to
transplantation
A detrimental effect of sensitization on wait time was
reported in the 3 studies [24,49,75], reporting non-
significant increases in wait time in sensitized patients
compared with non-sensitized patients. Overall, sensitization
was linked with longer wait times compared with non-
allosensitized patients.
Data from the USRDS 2010 annual report suggested
that, alongside a general increase in the median wait time
to transplantation in all patients in the last 20 years, wait
time was increased further in patients with allosensitization
compared with patients without allosensitization [27]. The
USRDS 2011 annual report indicated a trend for increased
median wait time to transplantation with increasing
allosensitization (PRA levels of 0%: 1.86 years; 1–9%:
1.84 years; 10–79%: 2.09 years; ≥80%: 2.88 years) [76].
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Primary Data Used to Calculate Average Graft Survival,
Subgroup Data Presented by Number of Transfusions as Defined in the Study
1 106 0 = 91.7% (n = 33), 1 matched = 90.3% (n = 28), 1 mismatched = 92.3% (n = 31)
> 1 1409 0 + CsA = 90.13% (n = 338), 0–CsA = 91.61% (n = 142), random + CsA = 93.65% (n = 295),random – CsA  = 90.13% (n= 137), DST + CsA = 90% (n = 387)
> 1 416 0 = 90.1% (n = 204), > 1= 86.4% (n = 212)
1–5 and > 10 4015 0 = 93% (n = 681), 0 group 1 = 84% (n = 369), 1–5 = 85% (n = 301), 1–5 group 1 = 73% (n = 507),> 5 = 91% (n = 838), > 5 group 1 = 83% (n = 726)
≥ 3 120 0 = 87.5% (n = 60), > 1 = 93.3% (n = 60)
1–5, 5–10
and > 10 1078
0 = 86.9% (n = 149), 1–5 = 85.5% (n = 405), 5–10 = 80.5% (n = 146), > 10 = 76.1% (n = 209)
3 423 0 = 82 ± 5% (n = 218), > 1 = 90% (n = 205)
1–2, 3–5
and > 5 284
0 = 81.2% (n = 48), 1–2 = 82.3% (n = 70), 3–5 = 81.9% (n = 59), > 5 = 79.7% (n = 63)
1–4 and ≥ 5 365 White recipients: 0 = 82% (n = 67), 1–4 = 84% (n = 83), ≥  5 = 80% (n = 48)Black recipients: 0 = 72% (n = 30), 1–4 = 68% (n = 29), ≥ 5 = 70% (n = 29)
5 units of red
blood cells 431
Living donor: 0 = 82.5% (n = 33), ≥ 1 = 93.7% (n = 89)
Deceased donor: 0 = 76.1% (n = 51), ≥ 1 = 77.3% (n = 177)
1–4 6674 0 = 71% (n = 1535), 1 = 75% (n = 433), 2 = 77% (n = 1172), 3 = 78% (n = 994), 4 = 78% (n = 883)
1–5 and > 5 212 0 = 64% (n = 31), 1–5 = 78% (n = 90), 6–10 = 97% (n = 31), > 10 = 91% (n = 15)
1–4 and > 4 8004 0–CsA = 61% (n = 213), 0 + CsA = 65% (n = 263), 1–4 – CsA = 63% (n = 845), 1–4 + CsA =77% (n = 957), > 4 – CsA = 64% (n = 1738), > 4 + CsA = 76% (n = 1482)
1–5, 6–10, 11–15
15728 0 = 48.3% (n = 1354), 1–5 = 64.3% (n = 4172), 6–10 = 66.7% (n = 2250), 11–15 = 66.8% (n = 826),16–20 = 68.1% (n = 403), > 20 = 64.2% (n = 794)16–2






















Figure 3 Graft survival at 12 months. (A) Difference between transfused and non-transfused patients. (B) Number of pre-transfusions.
*Significant difference as reported in the original publication; values have been rounded to the nearest integer, unless < 1. NOTE: Additional
calculation has been performed to allow for comparison between the populations of interest. Therefore, the numbers presented differ from those
presented in the primary source publications with the exception of Poli 1995 and Opelz 1997. NR: not reported; n = sample size with reported
outcome; CsA: cyclosporin A; DST: donor-specific transfusion.
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allosensitized patients (PRA ≥ 10%) compared with non-
allosensitized patients, with the longest wait time in pa-
tients with PRA levels between 20% and 79% [73].
Discussion
The pre-transplantation transfusion practice over the
last 20 years has been to minimize transfusions because
of risks outweighing benefits. Practice may change fol-
lowing the recent changes in payments for the manage-
ment of end-stage renal disease for Medicare patients
[4,5] and data from an AHRQ review [7,8] suggesting
that pre-transplant transfusion resulted in a neutral to
beneficial effect on graft rejection, graft survival, and pa-
tient survival compared with no transfusion. Although
the authors of the review acknowledged that the strength
of the evidence was low. While literature on pre-transplanttransfusions is abundant, the variety of patient characteris-
tics, questions addressed, methods used, data details
presented, and general study quality presents a challenge
for the assessment of the effects of pre-transplant transfu-
sions on patient outcomes. Our review aimed to address
this issue through the systematic identification of high-
quality studies (defined by peer review) that assessed the
relationship between pre-transplant transfusion and patient
outcomes of allosensitization, graft survival, and wait time,
and report if these relationships were observed in patient-
level registry data.
The knowledge that pre-transplant transfusions can cause
human leukocyte antigen (HLA) sensitization dates to the
early days of transplantation in the 1960s and 1970s [77].
More recent studies identified in this review complement
this position, providing clear evidence for the sensitizing ef-
















































































































73 PRA > 10% 7%
36 FCXM +ve 67%
153 Solid phase +ve None
64 Solid phase +ve 14%
471 B-cell CDC-XM +ve 13%
121 Solid phase +ve 12%
680 B-cell CDC-XM +ve None
30 PRA > 15% NR 
115 PRA +ve NR 
56 PRA ≥ 10%  None
24 Solid phase +ve NR 
49 Solid phase +ve NR 
992 B-cell CDC-XM +ve 15%
203 PRA ≥ 10%  NR 
200 FCXM +ve NR 
287 FCXM +ve 11%
230 PRA > 10%  None
153 Solid phase +ve None
287 FCXM +ve 11%
NR PRA > 20%  NR
155 Solid phase +ve 35%
122 Solid phase +ve NR
36 FCXM +ve 67%
100 Solid phase +ve NR
325 PRA > 10%  NR
153 Solid phase +ve None
63 Solid phase +ve 15%








Figure 4 Impact of allosensitization on graft rejection following kidney transplantation measured by acute rejection, chronic rejection,
and antibody-mediated rejection. *Significant difference as reported in the original publication; values have been rounded to the nearest
integer. NOTE: Additional calculation has been performed to allow comparison of populations of interest. Therefore, the numbers differ from the
primary publications with the exception of Mai 2009, Eng 2008, Pratico-Barbato 2008, Wang 2006, Le Bas-Bernardet 2003, Karpinski 2001, Scornik
2001, Hanish 2010, Riethmuller 2010, Cinti 2009, and Vlad 2009. CDC: complement-dependent cytotoxicity; CDC-XM: complement-dependent
cytotoxicity cross-match; FCXM: flow cytometry cross-match; NR: not reported; PRA: panel reactive antibodies; +ve: positive.
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transplant transfusion, with sensitization presumably
resulting from factors such as previous pregnancy or
prior transplantation. Additionally, the number of transfu-
sions was correlated with the incidence of sensitization.
Other studies have also reported that transfusions admi-
nistered to patients with previous alloantigen exposure,
such as pregnancies or transplants, and transfusions in
other settings (heart transplants or hematological malig-
nancies), often induce high sensitization [78]. Of note,
universal leukoreduction has not decreased sensitization
in patients to any significant degree [78]. Current data
from transplant registries confirmed the sensitizing effect
of transfusions, although these databases are limited re-
garding accurate assessment of the number of transfusions
and by lack of subgroup analysis [27,73,74,76]. Overall,the results imply that avoiding transfusions can signifi-
cantly decrease the incidence and degree of sensitization.
Numerous reports of the beneficial effects of blood
transfusions on graft survival were published in the
1970s and early 1980s [79]. In contrast, articles pub-
lished after 1984 reported a minor effect of blood trans-
fusions, either beneficial or detrimental. Only 2 papers,
dated 1987 and 1988, showed a more pronounced, non-
significant, beneficial effect (17% and 19% better graft
survival). However, a beneficial effect was observed when
graft survival rates with no transfusions were low. The
benefit was lower or non-existent when graft survival
rates were higher, such as current rates. Thus, im-
provements in graft survival comparable with those at-
tributed to the “transfusion effect” are now observed






























































































36 FCXM +ve 67%
121 Solid phase +ve 12%
471 B-cell CDC-XM +ve 13%
559 B-cell FCXM +ve 21%
56 PRA ≥ 10% None 
170 FCXM +ve 14%
182 Remote XM +ve 42%
992 B-cell CDC-XM +ve 15%
2552 PRA > 20% 100%
9031 B-cell CDC-XM +ve 12%
134 PRA ≥ 10% NR
36 FCXM +ve 67%
559 B-cell FCXM +ve 21%
287 FCXM +ve 11%
100 Solid phase +ve NR
36 FCXM +ve 67%
361 B-cell FCXM +ve 21%
2552 PRA > 20% 100%
992 B-cell CDC-XM +ve 15%
297 PRA > 10% 33%
402 Solid phase +ve NR
153 Solid phase +ve None
680 B-cell CDC-XM +ve None
471 B-cell CDC-XM +ve 13%
3659 PRA ≥ 5% NR
324 FCXM +ve None
198 B-cell FCXM +ve 21%
4048 Sensitized 9%
Figure 5 Relationship between allosensitization and graft survival at 1 year, 2 years, 3 years, 5 years, and 10 years. *Significant
difference as reported in the original publication; values have been rounded to the nearest integer. NOTE: Additional calculation has been
performed to allow for comparison between the populations of interest. Therefore, the numbers presented differ from those presented in the
primary source publications for Gupta 2008, Bryan 2007, Thompson 2003, Kimball 2011, Petero 2010, Lefaucheur 2010, Susal 2002, Kimball 2002,
and Opelz 2005. CDC: complement-dependent cytotoxicity; CDC-XM: complement-dependent cytotoxicity cross-match; FCXM: flow cytometry
cross-match; NR: not reported; PRA: panel reactive antibodies; +ve: positive.
Scornik et al. BMC Nephrology 2013, 14:217 Page 8 of 12
http://www.biomedcentral.com/1471-2369/14/217with pre-transplant transfusion. While a recent study
reported a beneficial effect of pre-transplant transfu-
sions with current immunosuppression protocols such
as cyclosporine [80], the results from this review sug-
gest that the graft outcome risk/benefit ratio has be-
come too high to consider blood transfusions when
they can be avoided. In addition, the beneficial effect
of transfusions on graft survival implies that most pa-
tients transplanted remained weakly sensitized or non-
sensitized after receiving transfusions; there are no reliable
data to estimate the number of patients who became
highly sensitized and were not able to receive a transplant
following transfusion.
The majority of studies, as well as registry data, sup-
ported the concept that sensitization leads to higher
rates of acute rejection, chronic rejection, antibody-
mediated rejection, and graft loss. Two of the 6 studiesthat did not find an increase in the incidence of acute
rejection with sensitization were restricted to evaluating
B cell cross-match, although most studies on B cell
cross-match reported that positive results led to de-
creased graft survival. Importantly, recent studies using
solid phase techniques reported that it is not the
sensitization per se that is harmful, but the presence of
DSAs that lead to increased rejection and graft loss. A
recent population-based study in over 2000 patients
reported that DSAs increased graft rejection and were
independent predictors of graft loss [81]. Since some
studies have not found a correlation between DSAs
and graft rejection, an emerging concept is that pre-
transplant DSAs confer a risk of poorer outcomes, but
the risk may be balanced by other factors in selected












































































































480 11% NR Solid phase +ve CDC -ve & FCXM -ve  
82 None NR Solid phase +ve FCXM -ve 
24 NR NR Solid phase +ve CDC-XM -ve
113 19% 18% Solid phase +ve CDC-XM -ve 
36 17% NR Solid phase +ve CDC-XM -ve 
27 56% 52% Solid phase +ve CDC-XM -ve 
38 26% NR Solid phase +ve CDC-XM -ve
50 NR NR Solid phase +ve CDC-XM -ve 














480 11% NR Solid phase +ve CDC-XM -ve 
38 26% NR Solid phase +ve CDC-XM -ve 
48 NR NR Solid phase +ve CDC-XM -ve 
113 19% 18% Solid phase +ve CDC-XM -ve 
94 67% NR Solid phase +ve FCXM +ve
118 NR NR Solid phase +ve CDC-XM -ve 
89 NR NR Solid phase +ve CDC-XM -ve 
38 26% NR Solid phase +ve CDC-XM -ve 




Figure 6 Impact of donor specific antibodies on graft rejection and survival. (A) Graft rejection. (B) Graft survival. *Significant difference
as reported in the original publication; †death censored graft survival reported; values have been rounded to the nearest integer. NOTE:
Additional calculation has been performed to allow for comparison between the populations of interest. Therefore, the numbers presented
differ from those presented in the primary source publications for Domingues 2010, Van 2008, Gupta 2008, and Lefaucheur 2010. CDC:
complement-dependent cytotoxicity; CDC-XM: complement-dependent cytotoxicity cross-match; FCXM: flow cytometry cross-match; NR:
not reported; -ve: negative; +ve: positive.
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http://www.biomedcentral.com/1471-2369/14/217Sensitization also leads to increased waiting times. Al-
though few papers have addressed this subject [24,49,75],
this has been well documented in registry data [76]. Mod-
erately sensitized patients’ wait times are close to non-
sensitized patients’ wait times. However, highly sensitized
patients continue to have excessive waiting times with the
concomitant risk of death while waiting [76].
The AHRQ review [7,8] reported that pre-transplant
transfusion resulted in a neutral to positive effect on graft re-
jection, graft survival, and patient survival compared withno transfusion. This review provides a historical analysis of
pre-transplant transfusion, but few recent studies that in-
volve current immunosuppressive medications, technologies
and techniques were included in the analysis. In contrast to
the AHRQ review, 2 recently published reviews reported re-
sults similar to our analysis indicating that blood transfu-
sions are sensitizing, and HLA sensitization reduces graft
survival and increases wait time for transplantation [82,83].
Overall, the evidence reviewed here suggests that blood
transfusions can lead to high sensitization and negate the
Scornik et al. BMC Nephrology 2013, 14:217 Page 10 of 12
http://www.biomedcentral.com/1471-2369/14/217benefits of transplantation, therefore they should not be en-
couraged as first-line therapy of anemia. Alternatives to
avoid transfusions should be considered whenever possible.
There are limitations with this review linked to limita-
tions within each included study, and the limitations of
registry data. Firstly, while most of the studies scored at
least fair quality as assessed by the Downs and Black check-
list [10], 6 studies were rated poor quality. Additionally, the
data of interest to this review were not always the primary
study endpoint, and may not be powered to detect differ-
ences between the subpopulations. Secondly, the detection
techniques used in studies were different, making it difficult
to directly compare results. The definition of sensitization
varied, ranging from PRA> 5% to ≥ 30%, as well as the arbi-
trary cut-off levels for solid phase assays. There was also a
lack of reporting on pregnancies or transplantations, which
has important implications since previous alloantigen ex-
posure can induce high levels of sensitization. Thirdly, in-
formation on immunosuppressant use was often
suboptimal to allow differentiation of outcomes by the use
or absence of such therapy. Furthermore, in some studies,
immunosuppressive regimen use was routine and had an
impact on transplantation outcomes. Fourthly, many stud-
ies presented data at multiple time points, with some
conflicting results across time points, resulting in subjectiv-
ity in determining the overall outcome direction for each
study (beneficial/detrimental). In addition, data were lack-
ing in some areas, for instance in the assessment of pre-
transplant transfusion and allosensitization on wait time to
transplantation. The limitations of registry data are well
reported, and in this study include no adjustment of
confounding factors and the applicability of data from non-
US registries to the US renal population.
Conclusions
This review implicates pre-transplant transfusions in a
number of untoward effects for potential transplant recipi-
ents. Avoiding transfusions whenever possible is now con-
sidered state-of-the-art practice for clinicians and surgeons
of all specialties. Avoiding transfusions is important for can-
didates of kidney transplantation because of the risk of
sensitization, with the concomitant possibility of longer
wait times, becoming ineligible for a particular live donor,
dying while on the waiting list, or having worse outcomes
after transplantation.
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